Other formats:
BibTeX
LaTeX
RIS
@article{1566639, author = {Besse, Lenka and Besse, Andrej and MendezandLopez, Max and Vašíčková, Kateřina and Sedláčková, Miroslava and Vaňhara, Petr and Kraus, Marianne and Bader, Jurgen and Ferreira, Renan B. and Castellano, Ronald K. and Law, Brian K. and Driessen, Christoph}, article_location = {PAVIA}, article_number = {9}, doi = {http://dx.doi.org/10.3324/haematol.2018.207704}, keywords = {metabolic switch; proteasome inhibitor; multiple myeloma}, language = {eng}, issn = {0390-6078}, journal = {Haematologica}, title = {A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis}, url = {http://dx.doi.org/10.3324/haematol.2018.207704}, volume = {104}, year = {2019} }
TY - JOUR ID - 1566639 AU - Besse, Lenka - Besse, Andrej - Mendez-Lopez, Max - Vašíčková, Kateřina - Sedláčková, Miroslava - Vaňhara, Petr - Kraus, Marianne - Bader, Jurgen - Ferreira, Renan B. - Castellano, Ronald K. - Law, Brian K. - Driessen, Christoph PY - 2019 TI - A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis JF - Haematologica VL - 104 IS - 9 SP - 415-419 EP - 415-419 PB - FERRATA STORTI FOUNDATION SN - 03906078 KW - metabolic switch KW - proteasome inhibitor KW - multiple myeloma UR - http://dx.doi.org/10.3324/haematol.2018.207704 L2 - http://dx.doi.org/10.3324/haematol.2018.207704 N2 - Proteasome inhibitors (PI) have evolved as the central backbone of treatment for multiple myeloma (MM), with first-in-class bortezomib and second- and third-generation PI, carfilzomib and ixazomib, having been approved for this indication. Proteasome inhibition disrupts the unfolded protein response to resolve excessive endoplasmic reticulum stress, but also leads to massive metabolic changes manifested by the induction of amino acid biosynthesis, an anti-oxidant response, lipogenesis and an increase in protein folding. In this sense, PI represent a unique class of drugs targeting cancer cell metabolism by affecting the balance between protein biosynthesis, folding and destruction. However, the adaptive changes in MM cell metabolism may provide the basis of resistance to PI, as high glycolytic activity or rewiring glucose metabolism is associated with bortezomib resistance in MM. ER -
BESSE, Lenka, Andrej BESSE, Max MENDEZ-LOPEZ, Kateřina VAŠÍČKOVÁ, Miroslava SEDLÁČKOVÁ, Petr VAŇHARA, Marianne KRAUS, Jurgen BADER, Renan B. FERREIRA, Ronald K. CASTELLANO, Brian K. LAW and Christoph DRIESSEN. A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. \textit{Haematologica}. PAVIA: FERRATA STORTI FOUNDATION, 2019, vol.~104, No~9, p.~415-419. ISSN~0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2018.207704.
|